secwatch.observer — SEC 8-K summary
======================================

Issuer:     CERO THERAPEUTICS HOLDINGS, INC. (CERO)
CIK:        0001870404
Form:       8-K
Filed at:   2025-05-29T23:59:59+00:00
Accession:  0001213900-25-048998
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CERO Therapeutics shareholders approve 1:20 reverse stock split, increase share reserve by 2M shares
--------------------------------------------------------------------------------

- Reverse stock split ratio set at 1:20, effective 12:01 a.m. ET on June 10, 2025, subject to regulatory processes.
- Shareholders approved amendment to 2024 Equity Incentive Plan, increasing authorized shares by 2,000,000 shares.
- Election of Class I directors Michael Byrnes and Lindsey Rolfe, M.D. to serve until 2028 annual meeting.
- Ratification of Wolf & Company, P.C. as independent registered public accounting firm for fiscal year 2025.
- Also approved issuance of shares upon exercise of February 2025 warrants and conversion of Series D preferred below market price.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025048998/0001213900-25-048998-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1870404/000121390025048998/ea0243837-8k_cero.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-048998

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer